International Journal of Medicine Research

International Journal of Medicine Research


International Journal of Medicine Research
International Journal of Medicine Research
Vol. 6, Issue 2 (2021)

An observational study of tolerability of rosuvastatin in patients with dyslipidemia


Supriyaa BB, N Bhakthavatchalam

Dyslipidemia is an independent modifiable risk factor for cardiovascular disease (CVD) in addition to genetic influences coupled with diet, inactivity, smoking & co-morbidities.(4) Rosuvastatin is a new generation HMG-CoA reductase inhibitor, which has substantial lipid lowering capacity, exhibits some unique pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages.(5,6) Cardiovascular disease (CVD) is a leading cause of death worldwide, and mortality due to CVD is higher in low- and middle-income countries.(1) In India, there has been an alarming increase in the prevalence of CVD over the past two decades so much so that it accounts for 24% of all deaths among adults aged 25-69 years. Indians have been found to develop CVD at a younger age than other populations.(2) The likely causes for the increase in the CVD rates include lifestyle changes associated with urbanization and the epidemiologic and nutritional transitions that accompany economic development. Dyslipidemia has been closely linked to the pathophysiology of CVD and is a key independent modifiable risk factor for CVD.(3) In India, there has been an alarming increase in the prevalence of CVD over the past two decades. Indians have been found to develop CVD at a younger age than other populations. The likely causes for the increase in the CVD rates include lifestyle changes and the epidemiologic and nutritional transitions that accompany economic development.
Download  |  Pages : 32-33
How to cite this article:
Supriyaa BB, N Bhakthavatchalam. An observational study of tolerability of rosuvastatin in patients with dyslipidemia. International Journal of Medicine Research, Volume 6, Issue 2, 2021, Pages 32-33
International Journal of Medicine Research